Interobserver variability of Ki-67 measurement in breast cancer

Journal of Pathology and Translational Medicine

Volumn 50, Issue 2, 2016, Pages 129-137

  Chung, Yul Ri ^a   Jang, Min Hye ^b   Park, So Yeon ^a,b   Gong, Gyungyub ^c   Jung, Woo Hee ^d   Kwon, Sun Young ^e   Kwon, Youngmee ^f   Kim, Dae Cheol ^g   Kim, Dong Sug ^h   Kim, Eun Kyung ⁱ   Kim, Wan Seop ^j   Kim, Yee Jeong ^k   Kim, Chungyeul ^l   Kim, Ji Young ^m   Kim, Hee Jung ⁿ   Do, Sung Im ^o   Maeng, Young Hee ^p   Park, Kyeongmee ^q   Park, So Young ⁿ   Bae, Young Kyung ^r   Suh, Kwang Sun ^s   Shim, Jeong Yun ^m   Oh, Hoon Kyu ^t   Yoo, Jin Ye ^u   Yoon, Hye Kyoung ^q   Lee, Ah Won ^v   Lee, Ji Shin ^w   Lee, Hyun Ju ^x   Lee, Hee Jin ^y   Yim, Hyunee ^z   Chun, Yi Kyeong ^aa   Jung, Min Jung ^ab   Cho, Eun Yoon ^ac   Jeen, Yoon Mi ^x   Choi, Hyun Joo ^ad   more..

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Keimyung University   (South Korea)

^f National Cancer Center   (South Korea)

^g Dong A University   (South Korea)

^h Dr Kim Medicos Clinic   (South Korea)

ⁱ Eulji University   (South Korea)

^j Konkuk University School of Medicine   (South Korea)

^k National Health Insurance Corporation   (South Korea)

^l Korea University College of Medicine   (South Korea)

^m CHA University   (South Korea)

ⁿ Mizmedi Hospital   (South Korea)

^o School of Medicine   (South Korea)

^p Jeju National University School of Medicine   (South Korea)

^q Inje University College of Medicine   (South Korea)

^r Yeungnam University College of Medicine   (South Korea)

^s Chungnam National University   (South Korea)

^t Catholic University of Daegu   (South Korea)

^u Saegyaero Hospital   (South Korea)

^v The Catholic University of Korea   (South Korea)

^w Chonnam National University   (South Korea)

^x Soonchunhyang University College of Medicine   (South Korea)

^y Asan Medical Center   (South Korea)

^z Ajou University Medical CentSuwon   (South Korea)

^aa Dankook University College of Medicine   (South Korea)

^ab Kosin University   (South Korea)

^ac Sungkyunkwan University School of Medicine   (South Korea)

^ad The Catholic University of Korea   (South Korea)

more..

Author keywords

Breast neoplasms; Ki 67; Multicenter; Observer variation

Indexed keywords

KI 67 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CLINICAL ARTICLE; CORRELATION COEFFICIENT; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; ONLINE SYSTEM; TISSUE MICROARRAY; TISSUE SECTION;

EID: 84962439771     PISSN: 23837837     EISSN: 23837845     Source Type: Journal    
DOI: 10.4132/jptm.2015.12.24     Document Type: Article

References (23)

1. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007; 117: 3155-63.
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
4. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
5. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.
6. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
7. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-23.
8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.
9. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 1992; 25: 31-40.
10. Luporsi E, André F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012; 132: 895-915.
11. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-83.
12. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-75.
13. Penault-Llorca F, André F, Sagan C, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27: 2809-15.
14. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167-70.
15. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-64.
16. Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897-906.
17. Wong SC, Chan JK, Lo ES, et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. Arch Pathol Lab Med 2007; 131: 1047-55.
18. Zabaglo L, Salter J, Anderson H, et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 2010; 63: 800-4.
19. Ekholm M, Beglerbegovic S, Grabau D, et al. Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility. Histopathology 2014; 65: 252-60.
20. Fasanella S, Leonardi E, Cantaloni C, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 2011; 6 Suppl 1: S7.
21. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 1723-39.
22. Mohammed ZM, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012; 106: 383-8.
23. Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res 2014; 16: R35.